Equities

Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.035
  • Today's Change-0.001 / -2.78%
  • Shares traded1.97m
  • 1 Year change-62.57%
  • Beta--
Data delayed at least 20 minutes, as of Jul 26 2024 06:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

  • Revenue in AUD (TTM)0.00
  • Net income in AUD-46.82m
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acrux Ltd14.46m-709.00k19.19m43.00--3.39--1.33-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Immuron Ltd3.58m-3.88m23.94m6.00--1.36--6.69-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Little Green Pharma Ltd25.63m-8.15m29.87m----0.3846--1.17-0.0272-0.02720.08560.25740.27721.0512.29---8.82---9.74--53.18---31.81--1.39-18.900.0624--29.07--4.72------
Oncosil Medical Ltd355.30k-11.71m30.58m2.00--4.61--86.08-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Radiopharm Theranostics Ltd0.00-46.82m37.01m----0.5367-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Starpharma Holdings Ltd10.63m-8.40m39.59m50.00--1.15--3.73-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Medical Developments International Ltd33.49m-19.21m41.86m68.00--0.553--1.25-0.2226-0.22260.38820.8770.33481.016.18---19.20-6.67-22.18-7.4369.6469.90-57.36-23.551.93--0.0311--47.3713.1254.79---6.41--
Syntara Ltd9.83m-14.26m47.76m107.00--5.30--4.86-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Vitura Health Ltd119.67m9.40m53.56m121.005.651.3614.160.44750.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Data as of Jul 26 2024. Currency figures normalised to Radiopharm Theranostics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

3.87%Per cent of shares held by top holders
HolderShares% Held
Investors Mutual Ltd.as of 28 Jun 202417.81m3.87%
Data from 28 Jun 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.